Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: Rb and p53 status may help distinguishing well from poorly differentiated neuroendocrine neoplasms (NEN) and may predict response to chemotherapy. Studies correlating Rb/p53 genetic and immunohistochemistry were performed on high-quality frozen samples with high throughput techniques efficient for copy number determination. This situation differs from routine practice in which small deletions may be hard to detect on formalin-fixed paraffin-embedded (FFPE) samples with a gene panel approach.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Cros J
Authors: Chen R, Lacroix L, De Rycke O, Lacombe C, Cazes A,
Keywords: rb, p53, aggressive neuroendocrine tumors, biomarker,
Introduction: Neuroendocrine carcinomas (NECs) are a rare subgroup of neuroendocrine neoplasms that occasionally originate from gastro-entero-pancreatic (GEP) tract. Owing to their low incidence, evidences of the effectiveness of chemotherapy are scarce. Analogously to small cell lung cancer, platinum plus etoposide (Vp16) regimens are currently the standard treatment in first-line, while little data are available on the role of second-line treatment.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Bardasi C, Caputo F, Santini C, Cerma K, Casadei Gardini A,
Keywords: neuroendocrine carcinoma, irinotecan, survival, second line treatment, NEC, chemotherapy,
Introduction: MCC is a rare and aggressive cutaneous neuroendocrine cancer linked to exposure to the Merkel Polyomavirus (MCPyV). Cisplatin and VP16 chemo may be an effective treatment for metastatic MCC, but responses are often transient. The blockade of programmed death 1 (PD-1) immune inhibitory pathway by avelumab, an anti-PD-L1 checkpoint inhibitor, is being investigated in solid neoplasms. This strategy can also be of interest in MCC because these tumors often express PD-L1
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author: Pusceddu S
Authors: Femia D, Prinzi N, Vernieri C, Lo Russo G, Concas L,
Keywords: Merkel cell carcinoma, Avelumab,
Introduction: Little is known about the expression of PD-L1 an the immune infiltrate in neuroendocrine neoplasms of the lung.
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author: Julien H
Authors: Kossai M, Hadoux J, Louvet E, Sullivan I, Thomas de Montpreville V,
Keywords: PD-L1, lung, neuroendocrine, immune infiltrate.,
Introduction: Merkel cell carcinoma (MCC) is a rare and aggressive primary cutaneous neuroendocrine malignancy. Chemotherapy with cisplatin (CDDP) and etoposide (VP16) is an effective treatment for metastatic MCC.
Conference: 13th Annual ENETSConcerence (2016)
Presenting Author:
Authors: Puliafito I, Falsaperla D, Mare M, Blanco G, Memeo L,
Keywords: merkel cell carcinoma, somatostatin analogues, radiotherapy.,